BioLineRx Announces Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production, New Patent, When Issued, Will Be Valid Until December 2041
Portfolio Pulse from Benzinga Newsdesk
BioLineRx has received a Notice of Allowance for a U.S. patent on the manufacturing method of Motixafortide (BL-8040), enabling large scale production. The new patent will be valid until December 2041.

March 04, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The Notice of Allowance for a U.S. patent on the manufacturing method of Motixafortide (BL-8040) is a significant milestone for BioLineRx, enabling large scale production and potentially boosting the company's product pipeline.
The Notice of Allowance for a new patent is a critical regulatory milestone that can significantly impact BioLineRx's ability to produce Motixafortide at scale, potentially leading to increased product availability and revenue. The long validity period until 2041 also provides a prolonged competitive advantage and intellectual property protection, which are crucial for the company's valuation and investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100